10911results about "Anti-inflammatory agents" patented technology

The invention discloses a metal-doped carbon quantum dot as well as preparation and application of the metal-doped carbon quantum dot in a nano antibacterial agent, citric acid, urea and tea polyphenol are taken as precursors, metal salt is added, carbon dot synthesis and metal ion doping are synchronously completed in one step through a hydrothermal method, and the metal-doped carbon quantum dot is prepared; the surfaces of the metal-doped carbon quantum dots are negatively charged, and the metal-doped carbon quantum dots have peroxidase-like activity and catalase-like activity at the same time; the metal ions adopt any one of Fe < 3 + >, Cu < 2 + > and Ce < 3 + >; the metal-doped carbon quantum dots are in a sphere-like shape. The metal-doped carbon quantum dots prepared by the preparation method disclosed by the invention have peroxidase-like activity and catalase-like activity at the same time through precise doping of metal ions, and the two activities have a synergistic effect in an oral periodontitis microenvironment, so that a good antibacterial effect is achieved.

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

The invention discloses a plant lactobacillus. The plant lactobacillus has the characteristic of efficiently tolerating 30% (w / v) cistanche substrate. The invention also discloses a medicinal and edible composition consisting of 85 parts of cistanche deserticola, 5 parts of rehmannia, 5 parts of fructus alpiniae oxyphyllae and 5 parts of Chinese yam, the composition is fermented by using plant lactobacillus, and the cistanche deserticola fermentation liquor is prepared by adopting a multi-stage temperature fermentation process to ferment for 16 hours. A non-targeted metabonomics result shows that the phytobacterium plantarum activates an upstream channel for synthesis of phenylethanoid glycoside substances, and the abundance of forsythiaside B is increased by 133 times compared with that before fermentation. The fermentation liquor can achieve the functions of reproductive anti-aging, kidney protection and body endurance improvement by down-regulating COX-2a and TGF-beta-1 gene expression.

The invention provides a benzofuranone compound as well as a pharmaceutical composition and application thereof, and relates to the technical field of medicines. The benzofuranone compound is a compound as shown in a formula I, a stereoisomer thereof, a tautomer thereof, a crystalline hydrate thereof, a solvate thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof. The benzofuranone compound and the pharmaceutical composition and the pharmaceutical preparation prepared from the benzofuranone compound can prevent or treat organ injury diseases, and have good treatment effects in kidney injury, liver injury, lung injury, brain injury and heart injury.

The invention belongs to the technical field of bioengineering, and particularly relates to leuconostoc mesenteroides subsp. Mesenteroides FTCM002 and application thereof in preparation of dendrobium officinale leavening with the effects of reducing blood sugar, nourishing the stomach and resisting inflammation. Dendrobium officinale is subjected to enzymolysis and inoculated with the strain for fermentation, and the obtained fermented dendrobium officinale has the effect of inhibiting alpha-glucosidase; the gastric mucosal injury can be relieved, the expression of VEGF, IL-6, IL-8 and TNF-alpha in the gastric mucosal injury is reduced, and the effect of nourishing the stomach is achieved; the cell phagocytic rate can be increased, the NO concentration and the content of immune factors IL-6 and TNF-alpha can be increased, and the effect of enhancing the immunity is achieved; the expression quantity of IL-6, IL-1beta and TNF-alpha in inflammatory cells can be reduced, and the anti-inflammatory effect is achieved.

The invention belongs to the technical field of hair care products, and particularly relates to composite acid gel for scalp care and a preparation method thereof. Salicylic acid, glycolic acid, piroctone azelate olamine salt, echinacea purpurea-lactic acid bacteria yeast, an emulsifier and water are combined, wherein the echinacea purpurea-lactic acid bacteria yeast is prepared by performing enzymolysis on echinacea purpurea through bacillus subtilis protease and then performing aerobic fermentation with lactic acid bacteria. Salicylic acid, glycolic acid and azelaic acid in the composite acid gel are compounded, so that stimulation of salicylic acid is weakened, and the effect of dissolving hair follicle grease is reserved; glycolic acid and azelaic acid are added to accelerate keratin metabolism, regulate sebum secretion and create safe and healthy shielding for the scalp environment, and polysaccharide and flavonoid compounds in the echinacea purpurea-lactic acid bacteria leavening are beneficial to exerting the anti-oxidation and immune regulation effects of the echinacea purpurea-lactic acid bacteria leavening. Therefore, the composite acid gel provided by the invention is green, safe and non-irritant, the preparation method is simple and convenient, and the composite acid gel can be used for inhibiting bacteria and reducing scalp inflammation.

The invention provides an enzyme response type supramolecular PDRN-mini ECM liposome and a preparation method and application thereof.The enzyme response type supramolecular PDRN-mini ECM liposome comprises phospholipid, a membrane stabilizer, a supramolecular compound and an emulsifier, a water phase formed by the supramolecular compound and the emulsifier serves as an inner core, and the supramolecular compound is formed by PDRN and mini ECM through intermolecular acting force; the mini ECM is formed by self-assembly of collagen peptide, elastin and hyaluronic acid. The supramolecular PDRN-mini ECM liposome with uniform particle size and good stability is obtained through a microfluidic technology, the process is simple, the controllability is high, and amplification is easy.

The invention relates to ultra-small prussian blue nano-particles (T-USPB-C) carrying tirofian, a preparation method of the nano-particles and application of the nano-particles in preparation of drugs for reducing MVO and MIRI. According to the preparation method, the T-USPB-C is prepared by three steps. The T-USPB-C provided by the invention can carry tirofiban, and has catalase and superoxide dismutase simulated nano-enzyme activity. Moreover, the size of the nano-scale drug is required to reach a nano-scale size, and the drug can be efficiently cleared through kidney excretion, so that the potential long-term toxicity problem is minimized. The ultra-small prussian blue nanoparticle carrying the tirofian has an excellent active oxygen scavenging capability. Microvascular perfusion can be rapidly improved through the antithrombotic effect, then the protection effect is continuously achieved through the anti-oxidation and anti-inflammatory mechanism, and microvascular injury and MIRI are effectively prevented.

The invention discloses an implant-derived exosome which is prepared by the following steps: adding cleaned and crushed colored rice flour into a PBS (Phosphate Buffer Solution) with the pH value of 6-7.4, homogenizing at a high speed, adding alpha-amylase into rice milk, performing enzymolysis for 1-2 hours under the conditions that the pH value is 6-7.4 and the temperature is 90-97 DEG C, filtering, and standing filtrate overnight; carrying out gradient differential centrifugation at 4 DEG C, collecting supernate, filtering, carrying out ultracentrifugation on filtrate at 4 DEG C and 12000-15000g for 1.5-3 hours, and collecting precipitate; and re-suspending the precipitate, enriching by using an MWCO ultrafiltration tube with the molecular weight cut-off of 100kDa, collecting the precipitate at the bottom of the ultrafiltration tube, and re-suspending in a PBS buffer solution, thereby obtaining the product. The exosome can effectively inhibit the generation of inflammatory factors, has a good inhibition effect on various pathogenic bacteria, also has an anti-oxidation effect, and has application prospects in the fields of inflammation resistance, bacteria resistance, oxidation resistance and the like.

Provided in the present invention are compounds as VAV1 degradation agents and the use thereof. Specifically provided are compounds represented by formula (II), and tautomers, stereoisomers, pharmaceutically acceptable salts or prodrugs thereof. The compounds provided by the present invention have good efficacy, and can be used for preparing drugs for treating or preventing VAV1-related diseases.

The invention provides glycyrrhizic acid / glycyrrhetinic acid-triethanolamine composite hydrogel as well as a preparation method and application thereof, and belongs to the technical field of preparation of biological medicine carriers and composite materials. According to the invention, glycyrrhizic acid or glycyrrhetinic acid is taken as a raw material, triethanolamine is taken as a cross-linking regulating agent, and the composite hydrogel with stable mechanical properties, high drug loading efficiency and anti-inflammatory synergistic activity is prepared through a mild physical and chemical cross-linking reaction; the preparation process of the composite hydrogel does not need a toxic cross-linking agent, the reaction condition is mild, the raw materials are cheap and easy to obtain, and large-scale production can be realized; the composite hydrogel presents a multi-group ionic bond cross-linked structure, can be used as a carrier of a pH responsive drug, and has good practicability.

The invention discloses a composition for improving the stability of oleuropein in a solution as well as a preparation method and application of the composition. The composition comprises oleuropein and at least one stabilizer, and the stabilizer is selected from the group consisting of anisic acid, lactobionic acid, glycyrrhizic acid, 3, 3-thiodipropionic acid, N-acetyl-L-glutamine, propyl-cysteine and lauramidopropyl betaine; and the pH value of the aqueous solution of the composition is 4.0-8.0. The preparation method comprises the following steps: dissolving oleuropein in water, adding the stabilizer, and uniformly mixing. Through simple physical mixing, by utilizing the synergistic effect of the specific stabilizer and the oleuropein, the degradation and discoloration of the oleuropein in the storage process are remarkably inhibited. Experiments show that after the preferable composition is preserved for 30 days in an open manner, the retention rate of the oleuropein still reaches up to 80% or above, and is far superior to that of blank control and a traditional liposome wrapping method. The composition is simple and convenient in preparation process and low in cost, and provides reliable technical support for wide application of oleuropein in liquid products such as food, medicine and cosmetics.

The invention discloses a low-temperature vacuum microwave freeze-dried sinomenine hydrochloride preparation and a preparation method thereof in the technical field of pharmaceutical preparations, and solves the problems of long drying time, high energy consumption and poor product stability in the traditional freeze-drying technology. A vacuum microwave collaborative freeze-drying technology is adopted, microwave internal heating is achieved through a 2.45 GHz magnetron microwave generator and a rectangular waveguide tube under the conditions that the vacuum degree is 20-30 Pa and the plate layer temperature ranges from-40 DEG C to-35 DEG C, the microwave power density in the primary drying stage ranges from 0.3 W / g to 0.5 W / g, the microwave power density in the secondary drying stage ranges from 0.1 W / g to 0.3 W / g, and collaborative control over the microwave power, the vacuum degree, the temperature and the time is achieved in cooperation with a quaternary coupling precise control system. The preparation contains 50 mg of sinomenine hydrochloride, 100 mg of mannitol and 10 mg of sodium carboxymethyl cellulose grafted modified polyvinylpyrrolidone, the residual moisture is controlled to be 0.4-0.6%, the activity retention rate is 94-96%, and the drying time is shortened to 12-16 hours.

This invention relates to the field of pharmaceutical technology, specifically to a substituted pyridotriazole compound, its preparation method, and its uses. This specification discloses a substituted pyridotriazole compound that inhibits RIPK1 and / or MLK, as well as its pharmaceutically acceptable salts, stereoisomers, solvent compounds, or prodrugs. The compound is shown in formula (I), where the definitions of each group are detailed in the specification. Furthermore, this invention also discloses pharmaceutical compositions comprising this compound and their use in the preparation of medicaments for treating RIPK1-related diseases or conditions.

The invention belongs to the technical field of polypeptides and biological medicines, and particularly relates to a WK7 series antibacterial peptide and application thereof in the aspects of resisting bacteria and preventing and treating diabetic foot, pneumonia and septicemia. According to the invention, a linear peptide WK7-line with an amino acid sequence of WKRWKRW is used as a minimum active unit, and modification is carried out to form a plurality of linear modified peptides; meanwhile, a cyclic peptide WK7-cyl is formed on the basis of the linear peptide WK7-line through cyclization, and the cyclic peptide WK7-cyl is further modified to form an annular modified peptide. The linear peptide WK7-line, the linear modified peptide, the cyclic peptide WK7-cyl and the cyclic modified peptide jointly form the WK7-series antibacterial peptide, and the WK7-series antibacterial peptide is artificially synthesized polypeptide, is small in molecular weight, easy to synthesize, free of cytotoxicity, almost free of hemolysis risk, high in sterilization speed and broad-spectrum antibacterial property and can be used for preparing the antibacterial peptide. The traditional Chinese medicine composition has a certain effect on prevention and treatment of diabetic foot ulcer, pneumonia and septicemia.

The invention discloses a cationic lipid compound, a lipid carrier containing the same and application, and belongs to the technical field of gene therapy. The cationic lipid compound disclosed by the invention has a structure as shown in a formula I, or an isomer, a pharmaceutically acceptable salt and a prodrug thereof. The lipid nanoparticles have the advantages of stable nanostructure, uniform size distribution, good biological biocompatibility, high in-vivo and in-vitro mRNA delivery efficiency, selective organ targeting and the like. The cationic lipid reaction operation is simple, the raw materials are cheap and easy to obtain, and the cationic lipid has high safety, is beneficial to industrial production and quality control, and has a good application prospect.

The invention provides a cobalt monatomic nano-enzyme system modified by phospholipid polyethylene glycol carboxyl. The cobalt monatomic nano-enzyme system comprises a cobalt monatomic nano-enzyme composite core and phospholipid polyethylene glycol carboxyl compounded on the surface of cobalt monatomic nano-enzyme, the cobalt monatomic nano-enzyme composite core comprises a cobalt monatomic nano-enzyme and ginsenoside loaded on the cobalt monatomic nano-enzyme. The invention also provides a bifidobacterium synergetic cobalt monatomic nano-enzyme system which is formed by combining cobalt monatomic nano-enzyme with ginsenoside Rb1 and further delivering the cobalt monatomic nano-enzyme and ginsenoside Rb1 through bifidobacterium bifidum for targeted therapy of enteritis. The combination of Co SA and Rb1 can enhance the anti-inflammatory efficacy by adjusting a key immune signal pathway, and bifidobacterium bifidum can ensure targeted delivery of microbiota and promote intestinal barrier repair. The synergistic three-component strategy integrating monatomic nano-enzyme antioxidation, natural drug immunoregulation and probiotic targeting is provided, and a promising treatment platform is provided for accurate intervention of IBD.

The invention relates to the technical field of natural plant extracts, and particularly discloses a plant extract composition with anti-inflammatory and soothing effects and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following components in percentage by weight: 1 to 5 percent of radix cynanchi atrati extract, 1 to 3 percent of flos magnoliae extract, 1 to 5 percent of flos hibisci mutabilis extract, 0.5 to 1 percent of herba andrographitis extract, 1 to 3 percent of citrus peel extract, 0.5 to 1 percent of rhizoma paridis extract and the balance of solvent. Six plant extracts with different anti-inflammatory mechanisms are scientifically screened and proportioned, the extraction process is optimized, the plant extracts have a synergistic effect, and the anti-inflammatory effect is improved by adjusting the proportion; the six components respectively act on different links of inflammatory response to form a complementary anti-inflammatory network, the plant extract composition with multiple anti-inflammatory pathways and synergistic interaction is developed, and the problems of single anti-inflammatory effect, insufficient permeability and the like in the prior art are solved.

The invention relates to the technical field of cosmetic functional raw material preparation methods, in particular to a plant extract and an extraction method and application thereof. The invention provides a plant extraction method, which comprises the following steps: adding a glycol ether or polyhydric alcohol solvent containing 5-7 carbon atoms into a product containing phenolic acid compound components and lignan compound components, carrying out homogeneous reaction, carrying out heating extraction, and collecting the extract. By adopting a supramolecular technology, phenolic acid compound components can form a supramolecular solvent with glycol ether or polyol solvents containing 5-7 carbon atoms, and the supramolecular solvent is further combined with lignan compound components to form a supramolecular structure, so that the stability of an extracting solution is remarkably enhanced, the specific enrichment of the lignan compound components is realized, and the specific enrichment of the lignan compound components is realized. The problems that an existing extraction technology is poor in stability, poor in formula applicability, not prominent in effect and the like are successfully solved.

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The present invention relates to a binding agent capable of specifically binding and competitively inhibiting neutrophil elastase, the binding agent comprising an immunoglobulin single variable domain (ISVD), as well as related products, methods and uses, for example, methods and uses, particularly for the prevention, treatment or diagnosis of inflammatory diseases.

The invention discloses chiral ionizable lipid nanoparticles and a preparation method thereof, and belongs to the technical field of biomedical materials. The chiral ionizable lipid nanoparticle comprises chiral amino acid derived lipid, ionizable lipid, auxiliary lipid, cholesterol, a phospholipid polyethylene glycol derivative and an RNA (Ribonucleic Acid) drug, the preparation method comprises the following steps: dissolving chiral amino acid derived lipid in methanol, respectively dissolving ionizable lipid, auxiliary lipid, cholesterol and phospholipid polyethylene glycol derivative in ethanol, and mixing to obtain a total lipid organic phase; dissolving an RNA drug in DEPC water to obtain an RNA aqueous solution, and mixing the RNA aqueous solution with an acidic buffer solution to obtain an RNA aqueous phase; quickly mixing the total lipid organic phase and the RNA water phase, and standing and incubating; adding the mixed solution into a 3500 Da dialysis bag, taking 1 * phosphate buffer solution (PBS, pH = 7.4) as an external water phase, and dialyzing to obtain the chiral ionizable lipid nanoparticles. The lipid nanoparticles provided by the invention can enhance the RNA uptake efficiency, and have good application prospects in the treatment of systemic inflammation and other diseases.

The invention belongs to the technical field of nutritional compositions and cosmetics, and particularly relates to an anti-aging composition and application and a product thereof. The composition provided by the invention is composed of L-ergothioneine and alpha-ketoglutaric acid, or L-ergothioneine and alpha-ketoglutaric acid salt, or L-ergothioneine and alpha-ketoglutaric acid salt. Through the synergistic effect of the L-ergothioneine and the alpha-ketoglutaric acid or the alpha-ketoglutarate, the contents of Col I and hydroxyproline in skin tissues can be remarkably increased, the expression of TGF-beta1 is up-regulated and converted, the activity of MMP-1 is inhibited, meanwhile, the malondialdehyde level is reduced to enhance the oxidation resistance, the synthesis of hyaluronic acid is promoted, and the water content of the skin is increased. The composition is simple in component and simple and convenient in preparation process, can be prepared into various products such as cosmetics, health care products or medicines, is used for achieving the effects of resisting aging, moisturizing, resisting inflammation or resisting oxidation, particularly has an excellent improvement effect on skin photoaging induced by ultraviolet rays, and is wide in application prospect.

The invention discloses design and synthesis of a series of brain-targeted ginsenoside Rg1 derivatives and application of the brain-targeted ginsenoside Rg1 derivatives in treatment of Alzheimer's disease. According to the invention, ginsenoside Rg1 and polyethylene glycol with a specific chain length are covalently linked to successfully construct the derivative capable of enhancing the penetrating power of the blood-brain barrier. The series of derivatives provided by the invention not only solve the problems of poor brain targeting and insufficient stability of natural Rg1, but also can inhibit neuroinflammation by regulating and controlling an NLRP3 / caspase-1 signal channel in an LPS-induced neuroinflammation model, and finally, the learning and memory ability is remarkably improved. The product is simple and convenient in preparation process and good in biological safety, and a new candidate compound is provided for developing a new generation of Alzheimer disease treatment medicines.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

The present application belongs to the technical field of medicine, and particularly relates to the use of tetrahydrojatrorrhizine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis. Experimental results show that tetrahydrojatrorrhizine can effectively alleviate the foot swelling level of CIA rats, reduce the arthritis score, and inhibit the progression of rheumatoid arthritis. Blood routine analysis shows that the administration of tetrahydrojatrorrhizine reduces the number of immune cells in the blood and weakens the immune level of the body. In addition, the experimental results also show that tetrahydrojatrorrhizine can inhibit synovial hyperplasia and relieve joint damage. Therefore, tetrahydrojatrorrhizine has the prospect of being developed into an oral medicament for treating rheumatoid arthritis, provides more treatment options for clinically treating rheumatoid arthritis, and has important social and economic values.

Disclosed is a method of treating liver ischemia reperfusion (I / R) injury in a subject. In some aspects, the method comprises providing a subject suffering from liver I / R injury or at risk of suffering liver I / R injury; and administering to the subject one or more heparan sulfate (HS) compounds. In some aspects, the one or more HS compounds comprises about 5 to about 18 saccharide units, optionally about 12 to about 18 saccharide units. In some aspects, the one or more HS compounds comprises about 12 saccharide units.

The invention belongs to the technical field of microbial fermentation, and particularly relates to a lactobacillus rhamnosus fermentation composition, a preparation method and application of the lactobacillus rhamnosus fermentation composition in the aspects of improving the tumor cell induced inflammation level and preventing and inhibiting breast tumors. The invention provides a lactobacillus rhamnosus fermentation composition. The lactobacillus rhamnosus fermentation composition is prepared from a raw material and lactobacillus rhamnosus NKU ML1-2, the raw materials comprise raspberry, poria cocos, cape jasmine, rehmannia, liquorice and orange peel. The lactobacillus rhamnosus fermentation composition has the effects of nourishing yin and clearing heat, soothing liver and regulating qi, and strengthening spleen and stomach. Results of embodiments show that the lactobacillus rhamnosus fermentation composition can prevent proliferation, invasion and migration of breast cancer tumor cells to a certain extent, and has an improvement effect on the level of inflammation induced by the tumor cells.

Relates to the technical field of medicines, provides keratin CF5, a preparation method, a pharmaceutical composition and application thereof, and particularly relates to keratin CF5, a nucleic acid molecule for coding the keratin CF5, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method of the keratin CF5. The invention relates to a keratin CF5-containing pharmaceutical composition and application of the keratin CF5, nucleic acid molecules, expression vectors, host cells or the pharmaceutical composition in preparation of antipyretic and analgesic, cough-relieving and phlegm-eliminating drugs, anticonvulsion, antiepilepsy, blood pressure lowering drugs, anti-inflammatory drugs and antiviral drugs, in particular to application of the keratin CF5, the nucleic acid molecules, the expression vectors, the host cells or the pharmaceutical composition in preparation of antipyretic and analgesic drugs.